Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...
The stock's rise snapped a five-day losing streak.
Hosted on MSN12h
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...
14h
The 69-year-old actor opened up about his harrowing experience which took place during the pandemic on Joe Rogan's podcast.
Further to the announcement on 2 January 2025 (the "2.4 Announcement”) and the update on the potential combination of Poolbeg ...
ORG Partners LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.3% in the 4th quarter, ...
Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...
We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback